The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices by Westra, Inge M et al.
  
 University of Groningen
The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Westra, I. M., Oosterhuis, D., Groothuis, G. M. M., & Olinga, P. (2014). The effect of antifibrotic drugs in rat
precision-cut fibrotic liver slices. PLoS ONE, 9(4), [e95462]. https://doi.org/10.1371/journal.pone.0095462
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
The Effect of Antifibrotic Drugs in Rat Precision-Cut
Fibrotic Liver Slices
Inge M. Westra1,2, Dorenda Oosterhuis2, Geny M. M. Groothuis1, Peter Olinga2*
1 Pharmacokinetics, Toxicology and Targeting, Department of Pharmacy, University of Groningen, Groningen, The Netherlands, 2 Pharmaceutical Technology and
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Abstract
Two important signaling pathways in liver fibrosis are the PDGF- and TGFb pathway and compounds inhibiting these
pathways are currently developed as antifibrotic drugs. Testing antifibrotic drugs requires large numbers of animal
experiments with high discomfort. Therefore, a method to study these drugs ex vivo was developed using precision-cut liver
slices from fibrotic rat livers (fPCLS), representing an ex vivo model with a multicellular fibrotic environment. We
characterized the fibrotic process in fPCLS from rat livers after 3 weeks of bile duct ligation (BDL) during incubation and
tested compounds predominantly inhibiting the TGFb pathway (perindopril, valproic acid, rosmarinic acid, tetrandrine and
pirfenidone) and PDGF pathway (imatinib, sorafenib and sunitinib). Gene expression of heat shock protein 47 (Hsp47), a
smooth muscle actin (aSma) and pro-collagen 1A1 (Pcol1A1) and protein expression of collagens were determined. During
48 hours of incubation, the fibrosis process continued in control fPCLS as judged by the increased gene expression of the
three fibrosis markers, and the protein expression of collagen 1, mature fibrillar collagen and total collagen. Most PDGF-
inhibitors and TGFb-inhibitors significantly inhibited the increase in gene expression of Hsp47, aSma and Pcol1A1. Protein
expression of collagen 1 was significantly reduced by all PDGF-inhibitors and TGFb-inhibitors, while total collagen was
decreased by rosmarinic acid and tetrandrine only. However, fibrillar collagen expression was not changed by any of the
drugs. In conclusion, rat fPCLS can be used as a functional ex vivo model of established liver fibrosis to test antifibrotic
compounds inhibiting the PDGF- and TGFb signalling pathway.
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Introduction
During liver fibrosis, connective tissue accumulates progressive-
ly and affects the normal function of the liver. The hepatic stellate
cells (HSC) play a pivotal role in the development of liver fibrosis.
Upon chronic injury, HSC are activated and transdifferentiate
into myofibroblasts that have fibrogenic properties and are the
main producers of collagen [1,2].
During fibrosis, different signaling pathways are activated. The
two most important pathways in liver fibrosis are the platelet-
derived growth factor (PDGF)- and the transforming growth factor
beta (TGFb) signaling pathway. Activation of these pathways
results in proliferation of myofibroblasts and excess deposition of
collagen [3–5]. Therefore many compounds inhibiting one of
these pathways have been developed as potential antifibrotic
drugs, some of which entered clinical studies [6]. However no
effective medicines against end-stage liver fibrosis are available yet.
PDGF is the most important proliferative factor for HCS and
myofibroblasts in liver fibrogenesis. During transition of quiescent
HSC into activated HSC with a myofibroblast phenotype, they
release PDGF. This PDGF binds to the PDGF receptor on
activated HCS and activates the PDGF pathway, but not in
quiescent HSC, as they do not express the PDGF receptor [7]. In
addition, Kupffer cells and hepatocytes can increase the release of
PDGF and the expression of the PDGF receptor in HSC [8].
Furthermore, after HSC activation and differentiation, TGFb,
produced by hepatocytes and Kupffer cells induces a growth
stimulatory effect in transdifferentiated myofibroblasts, resulting in
extracellular matrix deposition [9].
In order to study the mechanism of fibrosis and the effect of
antifibrotic compounds, several in vitro models have been
developed. The use of precision-cut tissue slices as ex vivo model
to study fibrosis in different organs has recently been reviewed
[10]. The major advantages of the use of precision-cut tissue slices
are the presence of the intact organ architecture, cell-cell and cell-
matrix interactions and the potential to use human tissue and to
contribute to a large reduction in the use of laboratory animals for
testing antifibrotic drugs [11,12]. Recently, the early onset of liver
fibrosis was investigated using rat precision-cut liver slices (PCLS)
[13,14]. Long-term culture for 48 hours of PCLS, prepared from
livers from healthy rats, induced activation of HSC and induction
of fibrosis markers, which could be inhibited by several antifibrotic
compounds acting on the PDGF- signaling pathway but not by
compounds acting via the TGFb pathway [14].
The aim of the present study was to investigate whether PCLS
from livers of rats with established fibrosis (fPCLS) can be used to
investigate the antifibrotic effects of drugs. Previously we reported
that fPCLS from bile-duct ligated (BDL) rats with established
fibrosis showed progression of the fibrosis process during
incubation which could be inhibited by pentoxifylline, imatinib
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and dexamethasone [15]. Moreover it was shown that during
culture up to 48 hours, both parenchymal and non-parenchymal
cells in fPCLS from BDL rats remained functionally active. In the
present study, we investigated the efficacy of a series of antifibrotic
compounds inhibiting the PDGF- or the TGFb pathway in fPCLS
from BDL rats. The PDGF-inhibitors imatinib, sorafenib and
sunitinib are tyrosine kinase inhibitors that have antifibrotic effects
in vitro and in vivo in rats [16–18]. The TGFb-inhibitors
perindopril, an angiotensin converting enzyme (ACE) inhibitor,
valproic acid, a histone deacetylase inhibitor, rosmarinic acid and
pirfenidone, antifibrotic compounds that inhibit the TGFb
expression, and tetrandrine, which up-regulates smad7, also
demonstrated antifibrotic effects in vitro and in vivo in liver fibrosis
[19–24]. In addition, we also tested colchicine, which antifibrotic
effects were shown in HSC and cirrhotic rats [25]. Based on the
results, we conclude that fPCLS are an adequate model to test the
efficacy of antifibrotic compounds.
Materials and Methods
Ethics statement
Adult male Wistar rats (Ctrl:WI) were purchased from Charles
River (Sulzfeld, Germany).
The rats were housed on a 12 hours light/dark cycle in a
temperature-and-humidity-controlled room with food (Harlan
chow no 2018, Horst, The Netherlands) and water ad libitum.
The animals were allowed to acclimatize for at least seven days
before the start of the experiments. The experiments were
approved by the Animal Ethical Committee of the University of
Groningen. The rats were anaesthetized with isoflurane (Nicholas
Piramal, London, UK) and subjected to BDL [26], and all efforts
were made to minimize suffering.
Slice experiments
Three weeks after BDL, livers were harvested and used for
preparing liver slices in ice-cold Krebs-Henseleit buffer supple-
mented with 25 mM D-glucose (Merck, Darmstadt, Germany),
25 mM NaHCO3 (Merck), 10 mM Hepes (MP Biomedicals,
Aurora, OH, USA) and saturated with carbogen (95% O2/5%
CO2) using a Krumdieck tissue slicer [11]. fPCLS with a diameter
of 5 mm and a thickness of 250 mm were incubated up to 48 hours
in 1.3 ml of Williams Medium E (with L-glutamine, Invitrogen,
Paisly, Scotland) supplemented with 25 mM glucose and 50 mg/
ml gentamycin (Invitrogen), with the antifibrotic compounds, at
37uC and 95% O2/5% CO2 in 12-wells plates while gently shaken
[11]. As a control, slices were incubated for 1, 24 and 48 hours
with the solvent. After 24 hours the slices were transferred to new
12 wells plates with fresh medium. The slices were incubated with
the antifibrotic compounds imatinib (1–10 mM) (Novartis, Basel,
Switzerland), valproic acid (0.1–1 mM) (Sigma Aldrich, Zwijn-
drecht, Netherlands), perindopril (10–100 mM) (Sigma Aldrich),
pirfenidone (0.5–2.5 mM) (Sigma Aldrich), rosmarinic acid (120–
270 mM) (Sigma Aldrich), colchicine (30–200 nM) (Sigma Al-
drich), tetrandrine (1–10 mM) (Sigma Aldrich), sunitinib (0.5–
5 mM) (LC laboratories, Woburn, USA) and sorafenib (0.5–2 mM)
(LC laboratories) and were also transferred after 24 hours to new
plates with fresh medium containing the inhibitors. For mature
fibrillar and total collagen detection after the addition of
antifibrotic drugs, the highest concentration of the compounds
was used. Stock solutions of the compounds were prepared in
Milli-Q water or DMSO and diluted in the culture medium with a
final concentration of the solvent of #1%.
Viability
After incubation slices were transferred to 1 ml of a sonication
solution, containing 70% ethanol and 2 mM EDTA, snap frozen
in liquid nitrogen and stored at 280uC. To determine the
viability, ATP levels were measured in the supernatant of samples
homogenized for 45 sec in a Mini-BeadBeater-8 (Biospec,
Bartlesville, OK, USA) and centrifuged for 2 min. at 16.000 g,
using the ATP bioluminescence kit (Roche diagnostics, Mann-
heim, Germany) [27]. ATP values (pmol) were divided by the total
protein content (mg) of the slice estimated by Lowry (Bio-Rad RC
DC Protein Assay) [28]. Values for the control slices are expressed
relative to the slices before incubation (t = 0). Values displayed for
the antifibrotic compounds are relative values compared to the
related controls incubated for 48 hours.
Gene expression
To determine the antifibrotic effect of the compounds on the
fPCLS, Hsp47, aSma and Pcol1A1 gene expression was determined
using Quantitative Real-Time PCR. First, the total RNA of three
pooled snap-frozen slices was isolated using the RNeasy Mini Kit
(Qiagen, Venlo, The Netherlands). The amount of isolated RNA
was measured with the ND-1000 spectrophotometer (Fisher
Scientific, Landsmeer, The Netherlands). Reverse transcriptase
was performed with 1 mg RNA using the Reverse Transcription
System (Promega, Leiden, The Netherlands). The RT-PCR
reaction was performed in the Eppendorf mastercycler gradient
at 25uC for 10 minutes, 45uC for 60 minutes and 95uC for
5 minutes. The gene expression of Hsp47, aSma and Pcol1A1 was
determined using the primers (50 mM) en probes (5 mM) listed in
table 1 and the qPCR mastermix plus (Eurogentec, Maastricht,
The Netherlands). The Real Time PCR reaction was performed in
a 7900HT Real Time PCR (Applied Biosystems, Bleiswijk, The
Netherlands) with 1 cycle of 10 minutes at 95uC and 45 cycles of
15 seconds at 95uC and 1 minute at 60uC.
Ct values were corrected for the Ct values of the housekeeping
gene Gapdh (DCt) and compared with those of slices before
incubation (t = 0) for the untreated slices and for the slices treated
with the antifibrotic compounds with the control slices incubated
for 48 hours (DDCt). Results are displayed as fold change (22DDCt).
Table 1. Primers and probes.
Primer/Probe Sequence Accession number
Hsp47 Forward 59-AGACGAGTTGTAGAGTCCAAGAGT-39
Hsp47 Reverse 59-ACCCATGTGTCTCAGGAACCT-39 NM_017173
Hsp47 Probe 59-CTTCCCGCCATGCCAC-39
aSma Forward 59-AGCTCTGGTGTGTGACAATGG-39
aSma Reverse 59-GGAGCATCATCACCAGCAAAG-39 BC158550
aSma Probe 59-CCGCCTTACAGAGCC-39
Pcol1A1 Forward 59-CCCACCGGCCCTACTG-39
Pcol1A1 Reverse 59-GACCAGCTTCACCCTTAGCA-39 NM_053304
Pcol1A1 Probe 59-CCTCCTGGCTTCCCTG-39
Gapdh Forward 59-GAACATCATCCCTGCATCCA-39
Gapdh Reverse 59-CCAGTGAGCTTCCCGTTCA-39 XR_008524
Gapdh Probe 59-CTTGCCCACAGCCTTGGCAGC-39
doi:10.1371/journal.pone.0095462.t001
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Collagen 1 protein expression analysis by western
blotting
For the measurement of collagen 1 protein in fPCLS, 3 slices
were pooled and snap frozen in liquid nitrogen and stored at 2
80uC until analysis. After thawing, the slice tissue was lysed for 1
hour on ice with RIPA buffer (1 protease inhibitor cocktail tablet
(Boehringer Mannheim), in 250 ml of buffer pH 7.5, containing
50 mM Tris/HCl, 150 mM NaCl, 1% Igepal CA-630, 0.5%
sodium deoxycholate, 0.1% SDS). The tissue was homogenized on
ice by a Potter homogenizer and centrifuged for 1 hour at 4uC at
16.000 g. Protein concentrations were determined in the super-
natant using a Bio-Rad DC protein assay according to the
protocol. Lysates were diluted with 4 x SDS sample buffer (50 mM
TrisHCl pH 6.8, 2% SDS, 10% Glycerol, 5% b-mercaptoethanol,
0.05% bromophenol blue) and boiled for 2 minutes. Tissue lysate
(100 mg of protein) was size fractionated on a 7.5% Sodium
Dodecyl Sulphate Poly Acrylamide gel by electrophoresis and
transferred to an activated Polyvinylidene Difluoride membrane
(Bio-Rad). After blocking for 1 hour in Tris buffered saline
supplemented with 5% Blocking Grade Powder (Bio-Rad) and
0.1% Tween-20, immunodetection of collagen-1 (1:1000, Rock-
land Immunochemicals) was performed. Binding of the antibody
was determined using horseradish peroxidase conjugated second-
ary goat anti-rabbit and tertiary rabbit anti-goat antibody (Dako,
Heverlee, Belgium). Visualization was performed with Western
Lightning Plus-ECL (Perkin Elmer, Groningen, The Netherlands)
and equal protein loading was confirmed by immunostaining with
monoclonal anti B-actin (clone AC-74) (Sigma Aldrich Chemie
B.V., Zwijndrecht, The Netherlands). The data of the untreated
slices were expressed relative to the t = 0 value and the data of the
slices treated with the antifibrotic compounds were expressed
relative to that of slices incubated for 48 hours.
Fibrillar collagen staining
Sirius red staining histochemistry was performed on 4 mm
paraffin sections of formalin fixed fPCLS. Staining for fibrillar
collagens was performed using the picrosirius red dye (Sigma,
Gillingham, UK), which was quantitated using the Cell D
computer program (Olympus, Hamburg, Germany). Each bar
represents the average of the data of 3 different livers, and of each
liver, 3 slices were stained per condition and of each slice the
whole area of the section was analyzed for quantification. The data
were expressed relative to that of control slices incubated for
48 hours.
Total collagen assay by hydroxyproline measurement
After incubation, triplicate slices were pooled and snap-frozen in
liquid nitrogen and stored at 280uC until analysis. After weighing
the tissue, 100 ml of 6 M HCl was added and tissue was
hydrolyzed at 95uC for 20 hours. Hydroxyproline was measured
using the QuickZyme Total Collagen Assay (QuickZyme BioSci-
ences, Leiden, The Netherlands) following the manufacturers
protocol. Hydroxyproline content (mg) was corrected for the
weight of the slices. The data of the untreated slices were expressed
relative to the t = 0 value and the data of the slices treated with the
antifibrotic compounds were expressed relative to that of control
slices incubated for 48 hours.
Statistics
A minimum of three different BDL-livers was used for each
experiment, using slices in triplicate from each liver. As not all
drugs could be tested in the same liver and for each liver control
slices were included, the number of livers used for control slices is
larger than the number of livers incubated with compounds. The
results of the treatments were compared to the untreated controls
using the Student’s-t-test. The results are expressed as means 6
SEM.
A p-value ,0.05 was considered significant. Statistical differ-
ences were determined on relative ATP-, Western blot, Sirius red




Slices from BDL-livers showed increased ATP levels after 1
hour of incubation reflecting the recovery of the ATP levels after
the period of cold preservation and slicing. The ATP levels
remained constant until 24 hours and were slightly decreased after
48 hours (18% when compared to the 1 hour control) but were not
significantly different from 24 hours samples (fig. 1A). In PCLS
from BDL-livers directly after preparation, gene-expression of
fibrosis markers Hsp47, aSma and Pcol1A1 were significantly higher
than those in PCLS from healthy rat livers (data not shown).
Incubation of the fibrotic liver slices from the BDL rats was
accompanied by a further increase of the gene expression of
fibrosis markers after 48 hours compared to slices directly after
slicing (fig. 1B). Already after 24 hours of incubation the Pcol1A1
gene-expression was significantly elevated compared to fPCLS
directly after preparation (fig. 1B). Furthermore, after 48 hours,
also the protein expression of collagen 1 was increased compared
to freshly prepared slices (fig. 1C). Sirius red staining and
hydroxyproline content of the slices were increased after 24 and
48 hours of incubation (fig. 2A-D,N and fig. 3A).
Effect of PDGF-inhibitors on fibrotic PCLS
The ATP content of the fPCLS indicated that the different
concentrations of imatinib, sorafenib and sunitinib used in this
study, were not toxic in fPCLS from BDL rats (fig. 4A). Incubation
for 48 hours with increasing concentrations of these inhibitors
showed a significant concentration dependent decrease in the gene
expression of fibrosis markers Hsp47, aSma and Pcol1A1 compared
to 48 hours incubated control slices (fig. 4B). The gene expression
of Hsp47 in fPCLS, incubated for 48 hours with 5 mM of imatinib,
was even significantly lower than in the control fPCLS directly
after slicing and fPCLS incubated for 24 hours. Also, the aSma
gene expression of fPCLS incubated with 5 and 10 mM imatinib,
2 mM sorafenib and 5 mM sunitinib was significantly lower than
that of control fPCLS directly after slicing (fig. 4B). Moreover, in
fibrotic PCLS incubated for 48 hours in the presence of 5 mM
sunitinib, the gene expression of Hsp47 and Pcol1A1 was
significantly lower than that of control fPCLS incubated for
24 hours (fig. 2B). Collagen 1 protein expression was also
significantly decreased after 48 hours of incubation with the
PDGF-inhibitors compared to the non-treated fibrotic slices
(fig. 4C), while the Sirius red staining and the hydroxyproline
content were not changed compared to control incubation (fig. 2
and fig. 3).
Effect of TGFb-inhibitors on fibrotic PCLS
Perindopril, rosmarinic acid and tetrandrine had no effect on
ATP values of fPCLS, however, pirfenidone (0.5 mM) decreased
viability by 24% although only at the lowest concentration and
valproic acid showed a concentration dependent decrease in ATP
values up to maximally 45% at 1 mM compared to control fPCLS
(fig. 5A). All TGFb-inhibitors showed a concentration dependent
reduction of the gene expression of the 3 fibrosis markers (fig. 5B),
Antifibrotic Drugs in Fibrotic Liver Slices
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while 10 mM tetrandrine even decreased the aSma gene expression
to a level lower than that of control slices directly after sling and
control slices incubated for 24 hours (fig. 5B). On the contrary,
0.5 mM pirfenidone increased the gene expression of Hsp47 by
20% in fPCLS. All TGFb-inhibitors caused a decrease in collagen
1 protein expression (fig. 5C). However, the fibrillar collagen
content as detected by the Sirius red staining was not decreased by
the TGFb inhibitors and rosmarinic acid even slightly increased
the Sirius red staining compared to control fPCLS (fig. 2). The
total collagen content as detected by the hydroxyproline content
was only decreased after addition of rosmarinic acid and
tetrandrine (fig. 3).
Effect of Colchicine on fibrotic PCLS
Colchicine had no effect on the viability of fPCLS from BDL
rats during 48 hours of incubation (fig. 6A). Concentrations of
30 nM and 100 nM significantly increased the gene expression of
Hsp47 (fig. 6B), while aSma and Pcol1A1 gene expression, Sirius red
staining and collagen 1 protein expression were not changed after
incubation with colchicine (fig. 2 and 6). However, hydroxyproline
content was decreased after addition of colchicine (fig. 3).
Discussion
Recently, we showed that PCLS from healthy rat livers can be
used to study the early onset of liver fibrosis [14]. In this current
study we investigated whether this ex vivo model could also be
utilized to study the end-stage of liver fibrosis, by using fibrotic rat
PCLS. Incubation of fPCLS prepared from BDL rat livers resulted
in an increase of fibrosis markers in the liver slices after 48 hours.
Hence, although fPCLS directly after slicing of a BDL liver are
already fibrotic, during incubation an even further increase of
gene expression of Hsp47, aSma, Pcol1A1, protein expression of
Figure 1. The effect of incubation of fPCLS on viability, gene expression of fibrosis markers and collagen 1 protein expression. The
effect of incubation up to 48 hours on the viability (A) (n = 12), on the gene expression of fibrosis markers Hsp47, aSma and Pcol1A1 (B) (n = 13) and
on the collagen 1 protein expression measured by western blot (pictures are from a representative experiment) (C) (n = 10) of fibrotic PCLS from livers
of BDL rats. Error bars represent standard error of the mean (SEM). *p,0.05 vs 0 hours. #p,0.05 vs 1 hour.
doi:10.1371/journal.pone.0095462.g001
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collagen 1, fibrillar collagen and total collagen deposition was
observed, suggesting that further HSC activation and fibrogenesis
occurs, as was shown before [15]. The initial decrease in aSma
gene expression at 24 hours might be explained by an initial
improvement due to the termination of the bile duct ligation or
loss of fibroblasts and again an activation of HSC due to long-term
incubation.
Figure 2. Sirius red staining of control fPCLS and fPCLS incubated with antifibrotic drugs. Sirius red staining on paraffin embedded,
formalin fixed fibrotic PCLS directly after slicing (A), incubated for 1 hour (B), 24 hours (C) and 48 hours (D) and incubated for 48 hours with the
compounds imatinib (ima) (E), sorafenib (sor) (F), sunitinib (sun) (G), perindopril (per) (H), valproic acid (vpa) (I), rosmarinic acid (ra) (J), tetrandrine (tet)
(K), pirfenidone (pir) (L) and colchicine (col) (M).Quantification of sirius red staining (N). n = 3. Error bars represent SEM. *p,0.05 vs 48 hours.
doi:10.1371/journal.pone.0095462.g002
Figure 3. Hydroxyproline content of control fPCLS and fPCLS incubated with antifibrotic drugs. Hydroxyproline content in fPCLS
incubated up to 48 hours (A) and with addition of 10 mM imatinib (ima), 2 mM sorafenib (sor), 5 mM sunitinib (sun), 100 mM perindopril (per), 1 mM
valproic acid (vpa) 270 mM rosmarinic acid (ra), 100 mM tetrandrine (tet), 2.5 mM perindopril (pir) and 200 nM colchicine (col) (B). n = 3. Error bars
represent SEM. *p,0.05 vs 0h (A), *p,0.05 vs ctrl 48h (B).
doi:10.1371/journal.pone.0095462.g003
Antifibrotic Drugs in Fibrotic Liver Slices
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In this study we investigated the effect of a series of compounds
predominantly inhibiting the TGFb pathway (TGFb-inhibitors) or
the PDGF pathway (PDGF-inhibitors).
The PDGF-inhibitors imatinib, sorafenib and sunitinib clearly
showed antifibrotic effects as they significantly decreased the gene
expression of Hsp47, aSma and Pcol1A1 in fPCLS after 48 hours of
incubation. These compounds also showed antifibrotic effects in
the model of early onset of fibrosis in PCLS [14]. Moreover these
data confirm the data of Van de Bovenkamp et al. who also showed
a decrease in Pcol1A1 and aSma gene expression in fPCLS from
BDL rats after 24 hours of incubation with imatinib compared to
control slices without imatinib [15]. Collagen 1 protein expression
was also decreased after 48 hours of incubation, however the
PDGF-inhibitors did not decrease the fibrillar collagen and total
collagen levels. Suggesting that the decrease in collagen 1 is not
large enough to decrease the total collagen content. In the present
study the gene expression of aSma after 48 hours of incubation of
fPCLS with 5 mM imatinib was even lower than in the 24 hours
control slices, suggesting that imatinib not only inhibited the
increase of the fibrosis marker which occurred between 24 hours
and 48 hours of culture, but even further reduced the aSma
expression. This result is in line with in vivo studies where imatinib
Figure 4. The effect of PDGF-inhibitors in fPCLS on viability, gene expression of fibrosis markers and collagen 1 protein expression.
The effect of PDGF-inhibitors imatinib (n = 4), sorafenib (n = 4) and sunitinib (n = 4) on the viability (A), on the gene expression of fibrosis markers
Hsp47, aSma and Pcol1A1 (B) and on the collagen 1 protein expression (pictures are from a representative experiment) (C) of fibrotic PCLS from livers
from BDL rats incubated for 48 hours. Error bars represent SEM. Significant decrease: *p,0.05 vs 48h, #p,0.05 vs 0 hours, +p,0.05 vs 24 hours.
doi:10.1371/journal.pone.0095462.g004
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caused a reduction in the number of proliferating HSC and aSma
positive cells 48 hours after BDL surgery in rats [29]. In contrast
to the findings with fPCLS, in vivo this was accompanied by a
reduced Sirius red staining for fibrillar collagen [29], which may
be explained by the differences in experimental conditions, as in
our studies imatinib was given for 48 hours, 3 weeks after BDL
surgery, while in vivo imatinib was administered 1 day prior to BDL
and treatment was continued for 3 days. This time dependency
was also observed in BDL rats in vivo where a reduction in fibrillar
collagen, assessed by an aniline blue staining, by imatinib was
observed during the first 21 days after BDL, but not when
administered during 22–35 days after BDL [30]. To our
Figure 5. The effect of TGFb-inhibitors in fPCLS on viability, gene expression of fibrosis markers and collagen 1 protein expression.
The effect of TGFb-inhibitors perindopril (n = 5), valproic acid (n = 4), rosmarinic acid (n = 4), tetrandrine (n = 4) and pirfenidone (n = 5) on the viability
(A), on the gene expression of fibrosis markers Hsp47, aSma and Pcol1A1 (B) and on the collagen 1 protein expression (pictures are from a
representative experiment) (C) of fPCLS from livers from BDL rats incubated for 48 hours. Error bars represent SEM. Significant decrease: *p,0.05 vs
48h, #p,0.05 vs 0 hours, +p,0.05 vs 24 hours.
doi:10.1371/journal.pone.0095462.g005
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knowledge hydroxyproline has not been measured before after
imatinib treatment in BDL rats, but it was decreased after imatinib
treatment in a rat model of pig-serum induced fibrosis [16].
However in the latter study imatinib was administered directly at
the start of the treatment with pig-serum [16] when fibrosis was
not yet established, which might explain the different results of
hydroxyproline in fPCLS.
Sorafenib, reduced the gene expression of fibrosis markers in the
ex vivo fPCLS in accordance with results obtained in rats in vivo
[31,32]. However, Sirius red was not reduced in fPCLS whereas in
vivo reduced Sirius red staining was observed after two weeks
treatment with sorafenib, starting two weeks after BDL [31],
which may indicate that the lack of effect on fibrillar collagen in
our studies is due to the relatively short duration of the treatment.
Wang et al. reported a reduction in both collagen 1 and
hydroxyproline content in BDL rats treated with sorafenib during
week 3 and 4 of BDL [17], while in fPCLS collagen 1 was reduced,
but hydroxyproline content was not, which again may be
explained by the short duration of treatment in the fPCLS studies.
To date, sunitinib was not tested in vivo in BDL rats, however it
was investigated in vivo in a model of CCl4-induced fibrosis [18].
Although the pathophysiology of these two fibrosis models shows
some differences, the effect of the PDGF-inhibitor imatinib was
similar in both models [29,33]. Sunitinib reduced the collagen
deposition (Masson’s trichrome staining) and the gene expression
of aSma and collagens in CCl4 treated rats [18]. The antifibrotic ex
vivo effects of sunitinib are therefore in line with these in vivo results
with respect to the fibrosis markers and the collagen 1 deposition.
The lack of effect of sunitinib on the fibrillar and total collagen
deposition in the fPCLS could not be compared with in vivo data as
they are not available.
To summarize, all tyrosine kinase inhibitors reduced the
collagen 1 protein and gene expression of fibrosis markers after
48 hours of incubation in fPCLS compared to control fPCLS
incubated for 48 hours, however the fibrosis markers were not
reduced compared to control slices incubated for 1 hour. Thus,
this implies that the antifibrotic compounds inhibited the increase
of fibrosis markers during incubation. In addition, PDGF-
inhibitors had an effect on collagen 1 only and not on fibrillar
and total collagen levels, probably due to the short durations of
treatment in the fPCLS studies.
To investigate if TGFb-inhibitors were also effective in the
fibrotic PCLS model, the effect of perindopril, valproic acid,
rosmarinic acid, tetrandrine and pirfenidone was investigated. Ex
vivo perindopril treatment decreased aSma and Pcol1A1 gene
expression and decreased the amount of collagen 1, in line with
results obtained in vivo both in BDL induced as well as in CCl4
induced liver fibrosis [33,34]. Similar to the findings with the
PDGF-inhibitors also with perindopril the hydroxyproline content
was not decreased in fPCLS, whereas it was decreased in vivo which
might be explained by the longer treatment period of 21 days.
In vivo valproic acid was not investigated in BDL rats, however it
was studied in CCl4 treated mice [20]. The antifibrotic effect of
valproic acid was shown by a down-regulation of aSma and
Pcol1A1 in valproic acid treated CCl4 mice (valproic acid in
drinking water starting 2 days before CCl4 injections) [20]. The ex
vivo antifibrotic effect of valproic acid in rat fPCLS was
comparable with these in vivo findings, despite the use of a
different species, and was shown by a reduction in the amount of
collagen 1, an inhibition of Hsp47 and Pcol1A1 expression and a
tendency to reduce the aSma expression. Again a reduced Sirius
red staining was observed in vivo after valproic acid treatment [20],
and not in the fPCLS, possibly because of the different dosage
Figure 6. The effect of colchcine in fPCLS on viability, gene expression of fibrosis markers and collagen 1 protein expression. The
effect of colchicine (n = 4) on the viability (A), on the gene expression of fibrosis markers Hsp47, aSma and Pcol1A1 (B) and on the collagen 1 protein
expression (pictures are from a representative experiment) (C) of fPCLS from livers from BDL rats incubated for 48 hours. Error bars represent SEM.
*p,0.05 vs 48h.
doi:10.1371/journal.pone.0095462.g006
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regimen. The decreased viability of fibrotic PCLS after valproic
acid administration was also found before in healthy rat and pig
PCLS [14,35], which may have affected the results. Moreover
valproic acid is known to have hepatotoxic effects in mice in vivo
[36]. However, as RNA could be isolated and the expression of the
housekeeping gene was constant in time we included the 1 mM
valproic acid.
Also rosmarinic acid was not investigated before in a BDL rat
fibrosis model, but was investigated in a CCl4 rat model (6 weeks)
for stationary liver fibrosis [21]. As in our fPCLS, hydroxyproline
content was reduced in CCl4 rats treated with rosmarinic acid
[21]. The reason why fibrillar collagen was slightly increased in
fibrotic PCLS after treatment with rosmarinic acid needs to be
further investigated, as no papers about the effect of rosmarinic
acid on sirius red in liver fibrosis have been published yet.
A reduced amount of collagen 1, hydroxyproline content and
aSma, Hsp47 and Pcol1A1 was found in fPCLS after tetrandrine
addition, which is comparable with in vivo studies in BDL rats
[37,38]. Treatment of BDL rats with tetrandrine directly after
surgery, reduced the number of aSma positive cells [37,38], Sirius
red staining [37] hydroxyproline content [38] and the gene
expression of aSma and Col1A2 [37]. However, in the fPCLS
model, tetrandrine was added when the slices were already
fibrotic, which might explain the fact that Sirius red was not
reduced after tetrandrine treatment, as it can be assumed that the
formation of fibrillar collagen occurs after the synthesis of collagen.
Like the other TGFb-inhibitors, studies with pirfenidone
showed comparable results in vivo and ex vivo. Pirfenidone
treatment was investigated in vivo in 4 weeks BDL rats,
administered directly after BDL surgery [23] and 2 weeks after
BDL surgery [39]. A reduction in Sirius red staining and
hydroxyproline content [23] and gene expression of Col1A [39]
after treatment with pirfenidone was seen.
In conclusion, all five TGFb-inhibitors showed antifibrotic
effects in fibrotic rat PCLS which was comparable with the in vivo
effects of these compounds on liver fibrosis. Both Pcol1A1 gene
expression and collagen 1 protein expression was decreased after
addition of the TGFb-inhibitors. However, fibrillar collagen levels
measured by Sirius red were not decreased and hydroxyproline, a
measurement of total collagen was only decreased in slices treated
with rosmarinic acid and tetrandrine, indicating that these
compounds may also have effects on other collagens. In addition,
the effect of TGFb-inhibitors on stationary fibrosis is different
from the effect of these inhibitors on the early onset of liver fibrosis
in PCLS [14]. TGFb-inhibitors only slightly reduced the fibrosis
markers in the early onset of fibrosis in PCLS [14], which suggests
that the TGFb pathway plays a minor role in the early onset of
liver fibrosis in PCLS and a larger role in end-stage liver fibrosis in
fPCLS.
Colchicine slows down the microtubule mediated transport of
procollagen [40], which may explain its antifibrotic effect as
observed in BDL rats where colchicine reduced the connective
tissue volume (Masson’s trichrome staining) [41], reduced the
increased collagen deposition (trichrome staining) [42,43] and the
hydroxyproline content [43]. Also in the ex vivo model of fPCLS,
colchicine induced a decrease in total collagen content although
fibrillar collagens were not yet changed.
In this study the effect of the antifibrotic drugs on the collagen
protein content was assessed on three different levels, the amount
of collagen 1 (by western blotting), the total collagen content (by
hydroxyproline determination) and the amount of fibrillar
collagens (by Sirius red staining). Both PDGF-inhibitors and
TGFb-inhibitors reduced the collagen 1 deposition, while total
collagen was only decreased by the TGFb-inhibitors rosmarinic
acid and tetrandrine and fibrillar collagens (mature collagen) were
not changed by any of the drugs. Apparently collagen 1 synthesis is
primarily affected by these drugs, which is not yet detected by
Sirius red or hydroxyproline content as mature fibrillar collagens
do not only consist of collagen type I, but also type II, III, V and
XI [44] and with a hydroxyproline measurement all collagens are
measured [45]. Moreover reduction in mature fibrillar and total
collagen is not only dependent on the synthesis of collagen but also
on the rate of collagen breakdown, and therefore it may take more
than 48 hours for an inhibition of synthesis to become manifest.
From the results of this study it can be concluded that collagen 1
detection by western blot is the most sensitive method for the
detection of antifibrotic effects on collagen disposition in fibrotic
PCLS.
In conclusion, PCLS from fibrotic livers from rats 3 weeks after
BDL can be successfully used as a functional ex vivo model to study
molecular pathways in established liver fibrosis, as these fPCLS
remain viable and fibrosis markers continue to increase during
incubation. In addition, the in vivo observed antifibrotic effects of
drugs acting on the PDGF- and TGFb signaling pathway can
successfully be reproduced ex vivo on the gene expression of fibrosis
related genes and collagen I protein expression, indicating that this
ex vivo model is a useful model for preclinical studies to test the
effect of potential new antifibrotic drugs on these fibrosis markers.
This will increase the efficiency of these studies as dose response
studies of several drugs can be performed simultaneously with a
limited number of rats, which also greatly reduces the number of
laboratory animals utilized in fibrosis research. Further studies are
ongoing to investigate the application of human PCLS from
patients with liver fibrosis, which will be useful to identify species
differences and to further reduce the use of experimental animals.
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